Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148219 | 0.84 | PDE3B (0.47) | NPC1RAB9APDE3BPDE3AMAPK14 | |
| SCHEMBL3325880 | 0.82 | PDE3B (0.43) | RAB9APDE3BPDE3AMAPK14MAPK13 | |
| SCHEMBL27846904 | 0.78 | PDE3B (0.31) | PDE3BPDE3A | |
| SCHEMBL11229339 | 0.78 | L3MBTL1 (0.48) | RAB9AL3MBTL1SMN1; SMN2HSD17B10CCNB2 | |
| SCHEMBL27846461 | 0.78 | CYP1A2 (0.46) | NPC1RAB9APKMMAPK14MAPK13 | |
| SCHEMBL11220685 | 0.78 | CYP3A4 (0.42) | NPC1RAB9APDE3BPDE3AGAA | |
| SCHEMBL3322318 | 0.78 | KIF11 (0.50) | NPC1RAB9AMAPK14MAPK13MAPK12 | |
| SCHEMBL18448211 | 0.78 | CYP11B1 (0.43) | RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL11145941 | 0.77 | KDM4E (0.48) | NPC1RAB9APKMPDE3BPDE3A | |
| SCHEMBL29889819 | 0.77 | LMNA (0.46) | PKMPDE3BPDE3AMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-8541574-B2 | Organometallic complex, and light-emitting element, light-emitting device and electronic device using the organometallic complex | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20130079516-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079516-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079516-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20080312437-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABRATORY CO., LTD. | 2008-12-18 | — | — | US | disclosed |
| US-20080312437-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABRATORY CO., LTD. | 2008-12-18 | — | — | US | disclosed |
| US-20080312437-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Organometallic Complex | SEMICONDUCTOR ENERGY LABRATORY CO., LTD. | 2008-12-18 | — | — | US | disclosed |
| CN-1301973-C | Heterocyclic derivatives and medicines | NIPPON SHINYAKU CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | NPC1 2924/4885RAB9A 668/4885PKM 3238/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | NPC1 2924/4885RAB9A 668/4885PKM 3238/4885 |
| US-20080312437-A1 | Organometallic Complex, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Organometallic Complex | NR2E3, AP2M1, AP3M1 | NPC1 4227/4885RAB9A 2900/4885PKM 1834/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | NPC1 3074/4885RAB9A 653/4885PKM 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.